CAJ | 학술논문

目的：探讨肝动脉化疗栓塞（TACE）联合DC-CIK细胞治疗BCLC C期肝细胞癌的疗效。方法60例BCLC C期HCC患者随机分为治疗组与对照组，治疗组患者采用TACE联合DC-CIK治疗，对照组患者只行TACE治疗，比较两组患者的免疫功能、半年和1年生存率。结果治疗组全血T细胞亚群CD3+CD8+明显升高，CD3+CD4+明显下降，较治疗前差异有统计学意义（P<0.05）。两组半年生存率分别为67.9％、48.1%（P<0.05），一年生存率分别为53.6%、29.6%（P＜0.05）。结论 TACE联合DC-CIK细胞联合治疗比单纯TACE治疗效果更好，是BCLC C期肝细胞癌的一种有效的治疗方法。
목적：탐토간동맥화료전새（TACE）연합DC-CIK세포치료BCLC C기간세포암적료효。방법60례BCLC C기HCC환자수궤분위치료조여대조조，치료조환자채용TACE연합DC-CIK치료，대조조환자지행TACE치료，비교량조환자적면역공능、반년화1년생존솔。결과치료조전혈T세포아군CD3+CD8+명현승고，CD3+CD4+명현하강，교치료전차이유통계학의의（P<0.05）。량조반년생존솔분별위67.9％、48.1%（P<0.05），일년생존솔분별위53.6%、29.6%（P＜0.05）。결론 TACE연합DC-CIK세포연합치료비단순TACE치료효과경호，시BCLC C기간세포암적일충유효적치료방법。
Objective To investigate the efficacy of transarterial chemoembolization (TACE) combined with autologous DC-CIK cells in treating hepatocellular carcinoma(HCC) of BCLC C-stage. Methods A total of 60 cases with HCC in BCLC C-stage were randomly and equally divided into the study group (n=30) and the control group (n=30). TACE combined with autologous DC-CIK cells was employed in the patients of the study group, while only TACE was adopted in the patients of the control group. The immune function, six-month and one-year survival rates were determined, and the results were compared between the two groups. Results In the study group, the blood T lymphocyte subsets of CD3+CD8+ were significantly increased, while CD3+CD4+ were obviously decreased. When compared with the pretreatment levels, the differences were statistically significant (P<0.05). The six-month survival rate of the study group and the control group was 67.9% and 48.1% respectively (P<0.05), and the one-year survival rate of the study group and the control group was 53.6%and 29.6%respectively (P<0.05). Conclusion For the treatment of HCC in BCLC C-stage, the therapeutic effect of TACE combined with autologous DC-CIK cells is much better than that of pure TACE. Therefore, this therapy is an effective treatment for HCC in BCLC C-stage.